Diffuse midline gliomas (DMGs) are pediatric brain tumors with a very dismal prognosis since less than 5% of patients survive 2 years after diagnosis. Radiotherapy remains the standard treatment for DMG, and several combination chemotherapies and single-agent target therapies are currently being explored.